AbbVie’s Elahere has been approved in the European Union as a treatment for adults with advanced, platinum-resistant ovarian cancer.| Rare Cancer News
Ovarian cancer tumors' microenvironment was seen to actively suppress the anti-cancer work of immune T-cells by blocking their energy supply.| Rare Cancer News